Patent RU-2240843-C2 (RU)
Inventor: GEVONDJAN N M
IPC: A61N5/06
Filed: 2000-12-29
Granted: 2004-11-27
Abstract: FIELD: medicine; medical engineering. 
     SUBSTANCE: method involves applying coherent and incoherent irradiation of biological objects with natural radiation of optical bandwidth from X-rays to radio waves including supracutaneous and/or intravenous and/or extracorporal blood irradiation and/or that of its components and/or external and/or intratissular endoscopic irradiation of thymus and/or spleen and/or mucous membranes and/or lymph nodes and/or blood vessels. Selective irradiation and/or spatial extended areas of biological objects is carried out by means of luminous matrices relative to local lesion foci of given disease and/or directly and/or indirectly to central and/or peripheral immune system organs or combined action applied to a biological object by combining irradiation with other factors of physical and/or chemical nature and/or drugs. Optimum energetic and/or spectral parameters and/or doses of action are determined in preliminary test examinations as well as immunomodulating action directly in course and/or after treatment and/or treatment cycle duration are determined from changes in shares of high and low avidity antibodies in blood serum and/or biological object secrets when performing test examinations in vitro. When treating, it is done before, during and after treatment in vivo. Increase in high avidity antibodies share to 75-100% accompanied with drop in low avidity antibodies share to 0-25% is to be taken as criterion of immune correction success. Reduction in high avidity antibodies share to 5-25% accompanied with increase in low avidity antibodies share to 75-95% is to be taken as criterion of immunodepression success. Optimum treatment dose is determined from transition time determined from transition of all antibodies from one avidity state to the other one in vitro action, respectively. Degree of immunological insufficiency expressiveness, disease severity and surface area under radiation are also taken in consideration. Optimum treatment dose applied biological object is calculated from formula E s =KxTxBxS, where E s  is the session duration in min, K is the correction coefficient (is dependent of individual device), T - is the exposure time in min required for low avidity antibodies to be transferred into the high avidity state as a value determined in preliminary test blood serum and/or biological object secrets in vitro examination, B is the disease severity degree in score scale as 1 - without clinical manifestations, 2 light disease course, 3 - moderate severity degree, 4 - severe forms of the disease, S is the irradiated surface area. The device has optical treatment unit connected to power supply source unit and control unit. The control unit is additionally connected to biofeedback unit having sample uptake and preparation unit, analysis and correction unit producing information signals entering the program unit. The control unit has in vitro blood serum test action mode selection is carried out in programmed mode before treatment and immunocorrecting mode using parameters determined in course of test examination. Analysis unit has cell block, device for automatically measuring titers and optical unit as light guides and radiation receivers connected to the cells. Test examination and recording modes are available for studying absorption and/or scattering in sediments produced on cell bottoms. 
     EFFECT: enhanced effectiveness of treatment. 
     8 cl, 4 dwg, 4 tbl